Saltar al contenido
Portada » News » “First-In-Human” Clinical Trial Employing Adoptive Transfer of Autologous Thymus-Derived Treg Cells (thyTreg) to Prevent Graft Rejection in Heart-Transplanted Children.

“First-In-Human” Clinical Trial Employing Adoptive Transfer of Autologous Thymus-Derived Treg Cells (thyTreg) to Prevent Graft Rejection in Heart-Transplanted Children.

Esther Bernaldo de Quirós, Manuela Camino, Nuria Gil, Esther Panadero, Constancio Medrano, Juan Miguel Gil-Jaurena, Marjorie Pion, Giovanna Lombardi, Megan K Levings, Lori J West, Rafael Correa-Rocha.

Transplantation: July 2018 – Volume 102 – Issue – p S205

DOI: 10.1097/01.tp.0000542859.38902.af

Abstract

Immune allograft rejection remains the main obstacle to reach successful transplants.

Transfer of regulatory T cells (Treg) has acquired growing interest in attempts to prevent rejection.

However, the limited number and the differentiated phenotype of Tregs isolated from blood constitute important drawbacks for the effectiveness of this strategy.

In collaboration with several teams, we have explored the use of the thymic tissue, which is routinely discarded during pediatric cardiac surgery, as an alternative source of Tregs to be used as cellular immunotherapy in heart-transplanted children.

“First-In-Human” Clinical Trial Employing Adoptive Transfer… : Transplantation (lww.com)

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *